Braveheart Bio, Inc.

Braveheart Bio, Inc.

BRVE

NASDAQHealthcareBiotechnology

أحدث البيانات المتاحة

‏21.51 US$

+‏0.32 US$ · ‎+1.51‎%‎

تحميل

BRVE نظرة عامة على الشركة

ملف الشركة

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.